Skip to main content
Neumora Therapeutics, Inc. logo

Neumora Therapeutics, Inc. — Investor Relations & Filings

Ticker · NMRA ISIN · US6409791000 US Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2026-05-29 Declaration of Voting R…
Country US United States of America
Listing US NMRA

About Neumora Therapeutics, Inc.

https://neumoratx.com/

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to redefining neuroscience drug development. The company focuses on creating precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. Neumora utilizes its proprietary 'Precision Toolbox,' an integrated data science platform, to identify patient subtypes and develop targeted therapies with novel mechanisms of action. This approach aims to address the significant unmet medical needs in brain health by applying the principles of precision medicine. The company's pipeline includes navacaprant, a clinical-stage candidate for the treatment of Major Depressive Disorder (MDD).

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 97% confidence The document is a Form 8-K, Item 5.07, reporting the official tabulation of stockholder votes at the company’s Annual Meeting. It lists vote counts for director elections, audit firm ratification, and advisory votes. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-29 English
8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
Regulatory Filings
2026-05-07 English
S-8 - Neumora Therapeutics, Inc. (0001885522) (Filer)
Regulatory Filings Classification · 100% confidence The document is a calculation of filing fees related to Form S-8, which is a registration statement for securities to be offered under employee benefit plans. It includes details about the number of shares, offering price, and registration fees. This type of document is typically part of a regulatory filing related to securities registration and does not contain financial performance data, management discussion, or other report content. It is not an annual report, earnings release, or any other financial report type. It is a regulatory filing related to securities registration fees under the Securities Act of 1933. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is short and focused on fee calculation, consistent with RNS filings.
2026-03-30 English
10-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
Annual Report FY 2025
2026-03-30 English
8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically states that the company announced its financial results for the fourth quarter and full year ended December 31, 2025, and that a press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length is 3642 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing financial results with a press release attached is classified as an Earnings Release (ER).
2026-03-30 English
4 - NEUMORA THERAPEUTICS, INC. (0001885522) (Filer)
Director's Dealing
2026-02-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.